Mantle Cell Lymphoma

Javier Munoz, MD, MS, FACP, of the Mayo Clinic, considers the appropriateness for CAR T-cell therapy for a 66-year-old woman with relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, reacts to recent data and the potential to treat patients with relapsed or refractory mantle cell lymphoma with KTE-X19, an investigational CAR T-cell therapy.

Nilanjan Ghosh, MD, discusses the current unmet needs in mantle cell lymphoma and how Bruton’s tyrosine kinase inhibitors are being looked at to fill that need for patients with high-risk disease in the first line.

Lori A. Leslie, MD, discusses the current treatment options for patients with mantle cell lymphoma.

The frequency of mutations in patients with mantle cell lymphoma has a tendency to increase at clinical turning points like disease relapse and progression compared with at the time of diagnosis, according to a systemic review and meta-analysis.

Combining temsirolimus with a chemotherapy regimen as treatment of patients with relapsed or refractory mantle cell lymphoma is feasible, according to the phase 1b T3 clinical trial.

The FDA has approved brexucabtagene autoleucel for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

Lori A. Leslie, MD, discusses options for patients with relapsed/refractory mantle cell lymphoma.

In a presentation during the 2020 Debates and Didactics in Hematology and Oncology conference, Amelia A. Langston, MD, explained the issues with treating patients with relapsed mantle cell lymphoma and how the integration of chimeric antigen receptor T-cell therapy can be a solution to the problem.

The addition of bortezomib consolidation therapy or bortezomib maintenance to the immunochemotherapy regimen rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone improved progression-free survival in patients with mantle cell lymphoma in the post-transplant setting, according to a comparative analysis, CALGB/Alliance 50403 trial.

In an interview with Targeted Oncology, Matthew Davids, MD, MMSc, discussed the long-term follow-up results of ibrutinib in combination with umbralisib as treatment of patients with chronic lymphocytic leukemia and mantle cell lymphoma.

In an interview with Targeted Oncology, Gaël Roué, PhD, discussed the rationale for evaluating TG-1701 in combination with ublituximab and umbralisib in ibrutinib-resistant MCL.

"We are excited about cirmtuzumab’s potential for the treatment of patients with ROR1-expressing cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, HER2-negative breast cancer, and other solid tumors, and look forward to further advancing its development to benefit patients with significant unmet medical needs."

Patients receiving high-dose therapy for mantle cell lymphoma are at a higher risk of treatment failure if they have mutations in the TP53 or KMT2D genes, according to new research.

"When compared to ibrutinib, TG-1701 used at high doses retained notable antitumor activity in MCL cells with BTK C481S mutation, while it did not show superior activity than the first-in-class BTK [inhibitor] in in vitro and in vivo models of ibrutinib-resistant MCL with constitutive activation of the non-canonical NF-KB pathway.”

Michael Wang, MD, discusses the pharmacological profile of KTE-X19 in patients with high- or low-risk relapsed/refractory mantle cell lymphoma in the ZUMA-2 trial.

Compelling objective responses and safety results were demonstrated with the combination of cirmtuzumab and ibrutinib in cohorts of patients with mantle cell lymphoma and chronic lymphocytic leukemia, who were treated in the phase 1b/2 clinical trial.

The autologous anti-CD19 CAR T-cell therapy KTE-X19 had a pharmacodynamic profile associated with efficacy and treatment-related neurological events in patients with relapsed/refractory mantle cell lymphoma, according to data from the ZUMA-2 clinical trial.

“Our study demonstrates that venetoclax is a potential salvage therapy in multiply relapsed patients with MCL. The majority (92%) patients in this study were exposed to BTKi, 66% were BTKi refractory, and these patients exhibited poor outcomes."

Andre Goy, MD, discusses the different BTK inhibitors as treatment of patients with relapsed/refractory mantle cell lymphoma.